
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Newport Beach, Calif. - A rare case of mucinous nevus was diagnosed in a 13-year-old autistic child, according to Dr. Peyman Ghasri, a resident at the University of California at Irvine.